Kiran Mazumdar Shaw is clear about the responsibility of Pharma companies. She says they don't have the luxury to be selective about what data they share with the public, simply because public money is involved. This EXCLUSIVE interview to Govindraj Ethiraj delves into who should get vaccines first - the young or the vulnerable?
- Whether it's possible to shrink the regulatory processes and timelines in vaccine or drug delivery for emergency use?
- Challenges of managing multiple vaccine deliveries with our constrained public health resources
- The need for a Pandemic Preparedness Technology Platform,
- Ongoing public health challenges triggered by the pandemic and our attempts at meeting them.
- How innovation can tackle a public health crisis like Covid19.
Referring to her own experience with Biocon's Itolizumab - a drug that ultimately did not become a part of Covid19 clinical management protocol, she says they got emergency use authorisation because, "We were able to demonstrate safety and showed some amount of efficacy".